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Abstract  
Background: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy for which 
there are few treatment options. Linsitinib (OSI-906) is a potent, oral small molecule 
inhibitor of both IGF-1R and insulin receptor, which has shown acceptable tolerability and 
preliminary evidence of antitumor activity. In this phase 3 study, linsitinib was evaluated in 
patients with advanced ACC. 
Methods: This international, double-blind, placebo-controlled phase 3 study investigated 
linsitinib 150mg orally, twice daily versus placebo, randomized 2:1. The primary endpoint 
was overall survival (OS) and secondary endpoints included progression-free survival (PFS), 
disease control rate, best overall response, and duration of response. 
Findings: Of 139 patients enrolled, 90 were assigned to linsitinib and 49 to placebo. The 
trial was unblinded in March 2012 based on data monitoring committee recommendation. 
There was no difference between linsitinib and placebo in OS (median 323 vs 356 days; 
p=0·77, hazard ratio [HR] 0·94; 95% CI 0·61-1·44) or PFS (median 44 vs 46 days; p=0·3, HR 
0·83; 95% CI 0·56-1·21). However, 4 patients remained on linsitinib, and treatment led to 
disease control from 23 to >45 months in these 4 patients. Three of these patients had 
partial response as best response compared to no objective responses in the placebo 
group. Linsitinib was well tolerated and pharmacokinetic results showed rapid absorption 
after first dose and accumulation following continuous twice-daily dosing. Increases in IGF-
1 levels were observed in a higher proportion of patients in the linsitinib group versus the 
placebo group; however, neither drug exposure nor IGF-1 plasma levels correlated with 
clinical activity. 
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Interpretation: Although linsitinib did not increase OS and PFS in the overall population, the 
promising responses seen in individual patients indicate the therapeutic potential of 
inhibiting IGF-1R in ACC and merits further studies of linsitinib in this disease.  
Funding: Astellas  
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Introduction 
Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with an annual incidence of 
2 per million worldwide and an estimated 5-year survival rate of 16–44%.1,2 Surgical 
resection is the treatment choice in localized disease and is frequently combined with 
adjuvant mitotane to increase the chance for cure.3–5 For patients with unresectable 
tumors, available therapeutic options include mitotane (the only drug approved for the 
treatment of ACC), systemic cytotoxic chemotherapy, and radiation therapy. While several 
retrospective studies suggest an impact of mitotane on overall survival (OS),2,6–9 the 
observed magnitude of benefit remains unclear. A randomized trial in ACC has recently 
shown a significantly longer progression-free survival (PFS) with a combination of 
mitotane/etoposide, doxorubicin and cisplatin as first-line therapy versus 
mitotane/streptozocin combination, although the difference in OS did not reach 
significance.10 
Insulin-like growth factor-2 (IGF-2) overexpression is the most common molecular event in 
ACC and is present in some 90% of tumors.11–13 IGF-2 signals through the insulin-like growth 
factor-1 receptor (IGF-1R) and insulin receptor (IR) to initiate a downstream signaling 
cascade that drives proliferation, migration, and metastasis of ACC and other cancers.14 
Preclinical and phase 1 studies using a variety of IGF-1R inhibitors have shown promising 
results, suggesting that antagonizing IGF-1R signaling may be a valuable approach in 
treating ACC.15–17 
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Linsitinib (OSI-906) is a potent, oral, small molecule inhibitor of both IGF-1R and IR which 
has shown preliminary evidence of antitumor activity in a variety of solid tumors, with an 
acceptable tolerability profile.18–20 Notably, in a dose-finding, phase 1 study, linsitinib 
resulted in partial responses in two of 15 patients with ACC (79 total study patients).19 
We report here the results of an international phase 3 study evaluating linsitinib in patients 
with advanced ACC who received at least one but not more than two prior drug regimens. 
 
Methods  
Study design and endpoints  
This randomized, double-blind, placebo-controlled, phase 3 trial was conducted at clinical 
sites in nine countries: Australia (1), Canada (3), Germany (3), France (6), Italy (2), the 
Netherlands (3), Poland (1), the United Kingdom (2), and the United States (14). The study 
protocol and amendments were reviewed by the Institutional Review Board for each study 
site. The primary endpoint was OS following administration of linsitinib versus placebo, 
calculated from date of randomization. Secondary endpoints included PFS, disease control 
rate (DCR) and duration of disease control, duration of response, and best overall response 
rate. Disease control rate was calculated as the proportion of patients with a complete 
response (CR), partial response (PR), or stable disease (SD) at ≥6 weeks among all 
randomized patients. Safety, pharmacokinetics, and pharmacodynamics of linsitinib were 
also evaluated as secondary endpoints. An independent Data Safety Monitoring Board 
regularly evaluated the study results including adverse events (AEs). 
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Patients 
Patients were eligible if they had histologically confirmed locally advanced or metastatic 
ACC not amenable to surgical resection; measurable disease according to RECIST; 
radiologically confirmed progressive disease in the 6 months prior to randomization; age 
≥18; Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) ≤2; 
predicted life expectancy ≥12 weeks; fasting glucose ≤150 mg/dl; and adequate 
hematopoietic, hepatic, and renal function. 
Patients must have had ≥1 but <3 prior drug regimens for locally advanced/metastatic ACC 
and were required to have received mitotane as neoadjuvant or adjuvant treatment, or as 
therapy for advanced/metastatic disease. 
Exclusion criteria included: type 1 diabetes mellitus or type 2 diabetes mellitus requiring 
insulinotropic or insulin therapy, prior IGF-1R inhibitor therapy, malignancy other than ACC 
within the past 3 years, history of significant cardiovascular disease, QTcF interval >450 ms, 
history of cerebrovascular accident within 6 months prior to randomization, and 
symptomatic brain metastasis. 
No other anticancer therapies, including mitotane, or investigational drugs were permitted 
during the study. Prior use of oral antihyperglycemic agents was allowed if the dose was 
stable ≥4 weeks prior to randomization. All patients received best supportive care for 
management of symptoms and toxicity and provided written informed consent.  
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Treatment and randomization 
Patients were randomized in a 2:1 ratio to either linsitinib or matching placebo, and were 
stratified according to the following parameters: prior systemic cytotoxic therapy for ACC 
(yes or no), ECOG PS (0–1 or 2), and use of ≥1 non-insulinotropic oral antihyperglycemic 
therapy at randomization (yes or no). Unique patient identification numbers were 
generated via a web-based, centralized randomization system and used to link each patient 
to the appropriate treatment group. 
The identity of the study agent was concealed and patients, investigators, site staff, and 
sponsor team were blinded to treatment. All patients received study agent (150 mg) twice 
daily (recommended phase 2 dose of lisitinib19) with food by continuous dosing schedule 
for 21-day treatment periods. Treatment was discontinued for disease progression or for 
unacceptable toxicity. Study agent was withheld for drug-related ≥grade 3 toxicity; at 
resolution of toxicity to grade 1, study agent was reintroduced at 100 mg twice daily (75 mg 
twice daily for second AE recurrence). The study agent could be reduced to 100 mg twice 
daily at the discretion of the investigator for clinically significant grade 1/2 drug-related 
toxicities or any grade unrelated toxicities, but could not be re-escalated. 
 
Assessments  
A physical examination, including ECOG PS assessment and vital signs, was performed at 
screening, pre-dose on day 1 of every 21-day treatment period, and post-treatment. To 
assess efficacy, tumor response and progression were evaluated by chest, abdomen, and 
pelvic CT scan (magnetic resonance imaging for contraindications) after every 2 treatment 
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periods (6 weeks) according to Response Evaluation In Solid Tumors (RECIST) criteria 
version 1.1,21 utilizing both local (real-time) and central (blinded) review. Safety was 
assessed by monitoring for any AEs, serious AEs (SAE), clinical laboratory data, vital signs, 
electrocardiograms, and physical examination. AEs were graded according to the National 
Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0, and relation 
to study treatment was judged by the local investigator. Pharmacokinetic data were 
evaluated from blood samples collected from all patients at pre-dose of day 1 of treatment 
periods 1, 2, and 3 (a treatment period was a 21-day dose cycle), and from the first 75 
randomized patients at pre-dose and 2, 4, and 8 hours post-dose on day 1 of treatment 
periods 1 and 2. Blood samples were collected for pharmacodynamic assessments at pre-
dose and 4 hours post-dose on day 1 of treatment period 1, and at pre-dose on day 1 of 
treatment periods 2 and 3. 
 
Statistical analysis 
Efficacy was assessed in the intent-to-treat population (all randomized patients). Safety was 
assessed in the safety population, which included all patients who received ≥1 dose of 
study drug and for whom any data were reported after first dose. The pharmacokinetic 
population included all patients who received active drug and for whom there was ≥1 
measurable concentration and the pharmacodynamic population included patients who 
received active drug and for whom there were sufficient data for analysis. OS and PFS were 
estimated using the Kaplan-Meier method and compared using the unstratified log-rank 
test. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a 
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proportional hazard model. Using a two-sided log-rank test at a significance level of 0·05, 
and an assumption of 80% power to detect a HR 0.58 for OS (median OS 274 vs 474 days), 
112 deaths were required to be observed from 135 enrolled patients. The interim analysis 
of OS was to be performed when 67 deaths were observed, by an independent statistician 
not affiliated with the sponsor.  
This study is registered with ClinicalTrials.gov, number NCT00924989. 
 
Role of the funding source 
As the sponsor of the study, Astellas financially supported the study, provided linsitinib and 
placebo free of charge, and was responsible for data collection and analysis. Astellas and a 
Scientific Steering Committee were involved in the study design. The authors had full access 
to all study data and prepared this report with Astellas, who had the right to review the 
report before publication. The authors had final responsibility for the decision to submit for 
publication. 
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Results  
Between December 2, 2009 and July 11, 2011, 139 patients were randomized (figure 1). 
One patient in the placebo group did not receive any treatment due to primary 
investigator-assessed general deterioration, and was excluded from the safety population. 
The trial was unblinded in March 2012 based on recommendation of the data monitoring 
committee. At that point, 6 patients were on study treatment, 2 of whom were receiving 
placebo. Patients were informed of the risk/benefit of continuing treatment. The 2 patients 
receiving placebo were not permitted to remain on the study. The 4 other patients chose to 
continue treatment with linsitinib. The database was locked December 4, 2012 with the 
analysis cutoff date July 11, 2012. Data from patients who continued with the study drug 
were available until July 2014. 
Overall, baseline demographic and disease characteristics were similar between the two 
treatment groups (table 1). Approximately 91% of patients had been previously treated 
with surgery, and 31% with radiotherapy. All patients received prior anticancer drug 
regimens including mitotane (table 1). 
At database lock, median OS was 323 days (95% CI 256–507) in the linsitinib group and 356 
days (249–556) in the placebo group (HR 0·94; 95% CI 0·61–1·44; p=0·771; figure 2). Based 
on independent radiologist review, median PFS was 44 days (95% CI 43–61) in the linsitinib 
group and 46 days (95% CI 43–64) in the placebo group (HR 0·83, 95% CI 0·56–1·21; 
p=0·303; figure 3), giving 17% risk reduction for the entire study population. Complete 
response was not achieved in any patient; PR was documented in 3 patients in the linsitinib 
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group (3·3%), but in none of the placebo group. DCR rate (CR+PR+SD) at 6 weeks was 32·2% 
(95% CI 22·8–42·9) in the linsitinib group vs 34·7% (21·7–49·6) in the placebo group, while it 
was 15·6% vs 8·2% at 12 weeks and 6·7% vs 0% at 24 weeks. The best change in target 
lesion size for patients in both arms is illustrated in a waterfall plot (figure 4). 
Of the 4 patients who continued on linsitinib after unblinding, 2 patients with a PR as a best 
response have rolled over to a separate linsitinib study in June and July 2014 following 45 
and 38 months on study drug. Another patient with PR as the best response discontinued 
study drug at 37 months due to an unrelated AE. Interestingly, all 3 responders had 
relatively low-grade ACC with Ki67 of 3, 10, and 20%. The fourth patient had SD as a best 
response, and was on study drug for 23 months.  
Predefined subgroup analyses of OS and PFS by sex, age, ECOG PS at baseline, smoking 
history, use of prior systemic and cytotoxic chemotherapy, and use of non-insulinotropic 
antihyperglycemic drug provided no evidence of differential treatment effect for linsitinib 
versus placebo.  
Mean and median overall drug exposure time was similar between the two groups, with a 
mean of 100 days and a median of 44·0 days for linsitinib, and a mean of 84·9 days and a 
median of 47·0 days for placebo. Disease progression was the most common reason for 
treatment discontinuation for both groups (76·7% for linsitinib and 83·7% for placebo), 
followed by AEs (13·3% and 4·1%), other medico-ethical reasons (3·3% and 8·2%), and 
patient-initiated withdrawal (2·2% and 4·1%).  
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Table 2 summarizes treatment-related AEs in both treatment groups over the entire study 
period. Treatment-related AEs were reported in 56% in the linsitinib and 44% in the 
placebo group and were generally low grade (table 2). Treatment-related AEs ≥grade 3 
were experienced by 17/90 patients (18·9%) in the linsitinib cohort, and 1/48 patients 
(2·1%) of the placebo cohort. The most common treatment-related AEs in the linsitinib 
group included fatigue, nausea, vomiting, and QTc interval prolongation (table 2). 
Hyperglycemia, one of the main treatment-related toxicities associated with linsitinib in 
preclinical studies, was observed in 3·3% of the patients in the linsitinib group and in 8·3% 
in the placebo group. Ten patients died while on treatment or within 30 days from the last 
dose, 5 (5.6%) in the linsitinib group and 5 (10.4%) in the placebo group, with malignant 
disease as the most common cause of death. No deaths in the linsitinib group were 
considered to be treatment-related.  Dose reductions and interruptions due to drug-related 
toxicity were reported for 12 (13·3%) and 11 (12·2%) patients in the linsitinib group, and for 
1 (2·1%) and 2 (4·2%) in the placebo group. 
Pharmacokinetic and pharmacodynamic profiles of linsitinib were evaluated as secondary 
endpoints. Pharmacokinetic parameters for linsitinib obtained after single (treatment 
period 1) and multiple (treatment period 2) doses are summarized in table 3. Linsitinib was 
absorbed with peak concentration (Cmax) occurring at a median Tmax of 2 hours following 
both single and multiple dose administration. Median exposure (area under the plasma 
concentration-time curve from time zero to the time of the last quantifiable concentration; 
AUClast) was higher in treatment period 2 than in treatment period 1.  
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IGF-1 plasma levels were measured in 133 patients, 86 in the linsitinib group and 47 in the 
placebo group. Increases in IGF-1 levels, a surrogate marker of IGF-1R inhibition, were 
observed in a higher proportion of patients in the linsitinib group versus the placebo group 
(figure 4). On days 22 and 43 in the linsitinib group, the median changes in IGF-1 
concentrations above pre-dose levels were 17·4% and 15·2%, respectively. However, 
neither drug exposure nor IGF-1 plasma levels correlated with clinical outcome of the 
patients. In addition, there was no difference in the exposure of linsitinib and plasma IGF-1 
levels between patients with a screening mitotane level <1 mg/L vs ≥1 mg/L (limit of 
quantitation). 
 
Discussion  
ACC is a rare and frequently fatal cancer, with limited therapeutic options.2,3,9 In this phase 
3 study we sought to confirm preliminary evidence of antitumor activity shown by linsitinib 
in patients with ACC.19 The results of the present study failed to show a statistically 
significant beneficial effect of linsitinib as second- or third-line therapy when compared to 
placebo on OS and PFS in patients with progressing ACC. Nonetheless, linsitinib treatment 
led to disease control from 23 to >45 months in 4 patients (4·4 %). Although there was no 
difference in DCR between the two groups at 6 weeks, 8 patients on linsitinib, but none on 
placebo, had PFS for >100 days. Furthermore, 3 patients achieved a partial response in the 
linsitinib group while no objective responses were observed in the placebo group. The AE 
profile in both treatment arms was consistent with the study population.  The rate of linsitinib-
16 
 
attributed toxicity-related dose modifications was low and comparable to the placebo 
group. 
Currently, no demographic, clinical, histopathological, or pharmacokinetic criteria have 
been identified that might predict response to linsitinib. Ongoing genomic characterization 
of tumor samples of treatment responders versus non-responders may reveal the basis for 
the observed sensitivity to linsitinib, and aid in future identification of patients most likely 
to respond to targeted anticancer agents inhibiting IGF-1R signaling. Of note, all 3 
responders had rather low-grade tumors with Ki67 of 3, 10, and 20%. An in vitro 
investigation correlating genetic characteristics of cancer cell lines with antiproliferative 
activity of figitumumab revealed that components of the IGF pathway play a pivotal role in 
determining the sensitivity of tumors to this agent.22 No particular signature for response 
to IGF-1R inhibition has yet been identified in ACC. A possible negative impact on response 
to platinum-based therapies has been found for high expression levels of the DNA repair 
gene excision repair complementation group 1 (ERCC1),23 and high ribonucleotide 
reductase large subunit (RRM1) gene expression had some association with poor efficacy of 
adjuvant mitotane therapy.24 
As expected, the pharmacokinetic profile of linsitinib was similar to that observed in a dose-
determining phase 1 study, with rapid absorption after oral dose and accumulation 
following continuous twice-daily dosing.19 In the present study, high variability in PK was 
observed  in treatment period 2, perhaps due to several factors including but not limited to 
age, weight, and concomitant medications.  
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While drug interactions may be critical determinants of drug efficacy in ACC treatment 
regimens, as suggested by the negative impact of mitotane treatment on sunitinib 
efficacy,25 mitotane blood level at baseline did not significantly influence exposure to 
linsitinib in the current study. The increase observed in serum IGF-1 levels is consistent with 
linsitinib inducing a systemic effect on the growth hormone (GH)-IGF axis. Whether such an 
endocrine effect is indicative of linsitinib-mediated inhibition of the tumoral IGF-1R is 
unknown. In contrast to the available anti-IGF-1R antibodies, linsitinib not only targets IGF-
1R, but also IR. Therefore, it was hypothesized that linsitinib may have a greater activity in 
ACC, because IGF-2 activates both IGF-1R and IR. However, for the vast majority of patients 
in this trial, these effects did not translate into better clinical outcome. 
Some anticancer drugs can be effective by blocking secondary survival pathways acquired 
during tumor progression. Evidence gathered from studies with drugs targeting the IGF-1R 
pathway suggests that combination therapy may provide additional benefits when 
compared with single-agent therapy. This can be achieved by simultaneously blocking 
pathways required for tumor growth or by preventing resistance to single pathway 
agents.26 The IGF-1R pathway is known to synergize with a number of other signaling 
pathways, including receptor co-signaling involving IGF-1R and epidermal growth factor 
receptor (EGFR).27 Studies in a number of tumor types have demonstrated synergistic 
effects by inhibition of both pathways simultaneously,27,28 but this could not be confirmed 
in clinical trials. In a recent phase 1 trial of the anti-IGF-1R antibody cixutumumab in 
combination with the mTOR inhibitor temsirolimus, disease stabilization in at least 6 
months was shown in 42% of patients with ACC.29 Synergy between the Wnt-signaling and 
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IGF pathway has also been explored in ACC,30 but no clinical data are yet available. Thus, 
further studies are needed to establish whether the combination of linsitinib with other 
targeted agents could lead to improved outcomes in patients with ACC.  
Treatment with linsitinib was generally very well tolerated. The majority of AEs were 
manageable according to standard clinical practice. Additionally, 4 patients were treated 
long term (>23 months) with linsitinib without increase in toxicity. Clinical toxicities of 
linsitinib reported in this study are consistent with those observed with antibodies 
targeting IGF-1R in patients with ACC, and included mainly fatigue and gastrointestinal 
toxicities.16,29 Despite inhibition of the IR, the number of patients who experienced serum 
blood sugar concentrations >160 mg/L was as low as 2 out of 90. 
Despite concerns regarding accrual to a phase 3 study in a rare cancer, the trial enrolled 
subjects rapidly, and was completed ahead of schedule. This should encourage those 
planning clinical trials to consider rare cancers and other “orphan” indications as a 
registration pathway. 
In conclusion, despite failing to show an effect on OS and PFS in the overall population, the 
promising responses seen in individual patients in our study indicate the therapeutic 
potential of inhibiting IGF-1R in ACC.  Further studies of linsitinib together with genetic 
profiling of patients responding to linsitinib, may pave the way for improved therapeutic 
options in ACC. 
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 Linsitinib (n=90) Placebo (n=49) 
Sex, n (%)   
  Male 30 (33·3) 19 (38·8) 
  Female 60 (66·7) 30 (61·2) 
Age (years; median, range) 
Ethnic origin 
50 (19·0–85·0) 48 (22·0–78·0) 
  Asian 1 (1·1) 1 (2·0) 
  Black 5 (5·6) 3 (6·1) 
  White 81 (90·0) 44 (89·8) 
  Other 3 (3·3) 1 (2·0) 
ECOG performance Status, n (%)   
 0 40 (44·4) 22 (44·9) 
  1 45 (50·0) 26 (53·1) 
  2 5 (5·6) 1 (2·0) 
Prior disease-related surgery, n (%)  83 (92·2) 43 (87·8) 
Time from initial diagnosis, months 
Mean (SD)  
Median (Range) 
 
41·9 (49·7) 
26·5 (3·8–276·9) 
 
27·9 (28·9) 
14·9 (3·3–129·3) 
Mitotane concentration, mg/L 
 Mean (SD) 
Median (Range) 
 
5·7 (5·2) 
4·8 (0–23·5) 
 
5·8 (5·3) 
3·6 (0·5–23·7) 
Prior radiotherapy, n (%) 29 (32·2) 14 (28·6) 
Prior anticancer drug regimens, n (%) 90 (100·0) 49 (100·0) 
Prior mitotane  
Neo-adjuvant 
 
1 (1·1) 
 
1 (2·0) 
  Adjuvant 33 (36·7) 21 (42·9) 
  Advanced/metastatic 81 (90·0) 43 (87·8) 
  Prior cisplatin-based   
chemotherapy 
47 (52·2) 30 (61·2) 
28 
 
  Prior streptozotocin 12 (13·3) 6 (12·2) 
  Prior other cytotoxic drugs 10 (11·1) 4 (8·2) 
Table 1: Demographic and baseline characteristics  
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 Linsitinib (n=90) Placebo (n=48) 
 Any grade 3 4 Any grade 3+4 5 
Any AE n (%) 50 (55·6) 16 (17·8) 1 (1·1)† 21 (43·8) 0 1 (2·1)‡ 
Fatigue 15 (16·7) 3 (3·3) 0 3 (6·3) 0 0 
Nausea 10 (11·1) 2 (2·2) 0 4 (8·3) 0 0 
QTc prolongation 9 (10·0) 0 0 1 (2·1) 0 0 
Vomiting 7 (7·8) 1 (1·1) 0 1 (2·1) 0 0 
Diarrhea 4 (4·4) 1 (1·1) 0 2 (4·2) 0 0 
Increased blood 
creatinine 
4 (4·4) 0 0 0 0 0 
Anorexia 3 (3·3) 1 (1·1) 0 0 0 0 
Arthralgia 3 (3·3) 0 0 0 0 0 
Asthenia 3 (3·3) 0 0 0 0 0 
Dry Skin 3 (3·3) 0 0 0 0 0 
 Alanine 
aminotransferase 
increased 
3 (3·3) 1 (1·1) 0 0 0 0 
Headache 3 (3·3) 0 0 4 (8·3) 0 0 
Hyperglycemia 3 (3·3) 2 (2·2) 0 4 (8·3) 0 0 
Hypokalemia 3 (3·3) 1 (1·1) 0 0 0 0 
 
Table 2: Drug-related adverse events reported in three or more patients in either treatment 
group*  
*For each preferred term, each subject was only counted once at maximum grade †Grade 4 AE reported as 
agitation and confusional state; ‡Grade 5 AE was reported as sepsis and megacolon. 
 AE = adverse event; QTc = corrected QT interval. 
 
 AUClast (ng*h/mL) Cmax (ng/mL) tmax (h) Clast (ng/mL) tlast (h) 
30 
 
Treatment period 1, day 1 
Evaluable, n 38 44 44 44 44 
Median  2571·1 782·5 2·0 130·2 7·9 
(range) (317·3, 6188·1) (85·2, 1883·0) (1·8, 8·2) (9·5, 1592·8) (3·3, 8·3) 
Treatment period 2, day 1  
Evaluable, n 33 40 40 40 40 
Median 5580·1 1091·1 2·0 332·4 7·9 
(range) (483·0, 26444·0) (80·9, 4542·8) (0·7, 4·0) (18·8, 4542·8) (0·7, 8·1) 
Table 3: Linsitinib pharmacokinetic parameters after single (treatment period 1) and multiple 
(treatment period 2) dosing*  
*Patients who received active drug, were within the first 75 randomized patients, and for whom the 
pharmacokineticist determined that there was sufficient data to calculate meaningful pharmacokinetic 
parameters (Extended Pharmacokinetics Analysis Set). 
AUClast = area under the plasma concentration-time curve from time zero to the time of the last 
quantifiable concentration; Clast = observed concentration at last time point; Cmax = maximum observed 
concentration; tlast = time of last quantifiable concentration; tmax = time to reach maximum observed 
concentration. 
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Figure 1: Patient disposition 
 
 
AE = adverse event; FAS = full analysis set; SAF = safety analysis set; PDAS = pharmacodynamic analysis set; 
PKAS = pharmacokinetic analysis set.  
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Figure 2: Overall survival  
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Figure 3: Progression-free survival based on independent radiologist review  
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Figure 4: Waterfall plot of best percentage change from baseline in sum of target lesion in 
linsitinib and placebo arms’ central review  
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Figure 5: IGF-1 concentrations as a percentage of pre-dose values over time on treatment* 
 
*0·17 is 4 hours post-dose. IGF-1=insulin-like growth factor 1. 
 
